These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38602320)

  • 21. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes.
    Lehmann BD; Colaprico A; Silva TC; Chen J; An H; Ban Y; Huang H; Wang L; James JL; Balko JM; Gonzalez-Ericsson PI; Sanders ME; Zhang B; Pietenpol JA; Chen XS
    Nat Commun; 2021 Nov; 12(1):6276. PubMed ID: 34725325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations.
    Guerini-Rocco E; Piscuoglio S; Ng CK; Geyer FC; De Filippo MR; Eberle CA; Akram M; Fusco N; Ichihara S; Sakr RA; Yatabe Y; Vincent-Salomon A; Rakha EA; Ellis IO; Wen YH; Weigelt B; Schnitt SJ; Reis-Filho JS
    J Pathol; 2016 Apr; 238(5):677-88. PubMed ID: 26806567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
    Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular analyses of triple-negative breast cancer in the young and elderly.
    Aine M; Boyaci C; Hartman J; Häkkinen J; Mitra S; Campos AB; Nimeus E; Ehinger A; Vallon-Christersson J; Borg Å; Staaf J
    Breast Cancer Res; 2021 Feb; 23(1):20. PubMed ID: 33568222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.
    Yang YS; Ren YX; Liu CL; Hao S; Xu XE; Jin X; Jiang YZ; Shao ZM
    Breast Cancer Res Treat; 2022 Jun; 193(2):319-330. PubMed ID: 35334008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer.
    Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z
    Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency and genetic basis of MHC, beta-2-microglobulin and MEMO-1 loss of heterozygosity in sporadic breast cancer.
    McEvoy CR; Seshadri R; Morley AA; Firgaira FA
    Tissue Antigens; 2002 Sep; 60(3):235-43. PubMed ID: 12445306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical signaling pathways of triple negative and triple positive breast cancers: What is new?
    Elsers DA; Masoud EM; Kamel NAMH; Ahmed AM
    Ann Diagn Pathol; 2021 Dec; 55():151831. PubMed ID: 34634762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
    Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
    Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer.
    Parvathareddy SK; Siraj AK; Ahmed SO; Ghazwani LO; Aldughaither SM; Al-Dayel F; Tulbah A; Ajarim D; Al-Kuraya KS
    Cells; 2021 Jan; 10(2):. PubMed ID: 33503961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
    BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling.
    Vishnoi M; Liu NH; Yin W; Boral D; Scamardo A; Hong D; Marchetti D
    Mol Oncol; 2019 Sep; 13(9):1913-1926. PubMed ID: 31216110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Sinn BV; Weber KE; Schmitt WD; Fasching PA; Symmans WF; Blohmer JU; Karn T; Taube ET; Klauschen F; Marmé F; Schem C; Stickeler E; Ataseven B; Huober J; von Minckwitz G; Seliger B; Denkert C; Loibl S
    Breast Cancer Res; 2019 Dec; 21(1):142. PubMed ID: 31829264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of heterozygosity in the HLA class I region in human pancreatic cancer.
    Ryschich E; Cebotari O; Fabian OV; Autschbach F; Kleeff J; Friess H; Bierhaus A; Büchler MW; Schmidt J
    Tissue Antigens; 2004 Dec; 64(6):696-702. PubMed ID: 15546343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microsatellite instability in Japanese female patients with triple-negative breast cancer.
    Kurata K; Kubo M; Kai M; Mori H; Kawaji H; Kaneshiro K; Yamada M; Nishimura R; Osako T; Arima N; Okido M; Oda Y; Nakamura M
    Breast Cancer; 2020 May; 27(3):490-498. PubMed ID: 31907878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.